Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC).

被引：2
|
作者：
Tang, Jie
Liu, XiaoLing
Gong, Youling
Zhu, Jiang
Huang, Meijuan
Ding, Zhenyu
Yu, Min
Tie, Yan
Li, Qiu
Wang, Yongsheng
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Oncol, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Canc, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21154
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
    Zhang, Bo
    Xu, Jianlin
    Zhang, Xueyan
    Gu, Ping
    Wang, Huimin
    Wang, Shuyuan
    Qian, Jie
    Qiao, Rong
    Zhang, Yanwei
    Yang, Wenjia
    Qian, Fangfei
    Zhou, Yan
    Lu, Jun
    Zhang, Lele
    Han, Baohui
    LUNG CANCER, 2018, 117 : 27 - 31
  • [32] Clinicopathologic features and immune microenvironment of non-small cell lung cancer with primary resistance to epidermal growth factor receptor-tyrosine kinase inhibitors
    Takashima, Yuta
    Sakakibara-Konishi, Jun
    Hatanaka, Yutaka
    Hatanaka, Kanako C.
    Ohhara, Yoshihito
    Oizumi, Satoshi
    Hida, Yasuhiro
    Kaga, Kichizo
    Kinoshita, Ichiro
    Dosaka-Akita, Hirotoshi
    Matsuno, Yoshihiro
    Nishimura, Masaharu
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC) A Systematic Review and Meta-analysis
    Raphael, Jacques
    Vincent, Mark
    Boldt, Gabriel
    Shah, Prakesh S.
    Rodrigues, George
    Blanchette, Phillip
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 440 - 445
  • [34] Impact of Local Therapy on Disease Progression and Survival Outcomes in Oligometastatic Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer (NSCLC) Treated with First Line EGFR Tyrosine Kinase Inhibitors (Tkis)
    Soon, Y. Y.
    Lee, C. C.
    Koh, W. Y.
    Leong, C. N.
    Tey, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E152 - E152
  • [35] Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
    Maria Martinez-Navarro, Elena
    Rebollo, Joseba
    Gonzalez-Manzano, Ramon
    Sureda, Manuel
    Evgenyeva, Elena
    Valenzuela, Belen
    Jose Fernandez, Francisco
    Forteza, Jeronimo
    Brugarolas, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (11): : 812 - 818
  • [36] Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wildtype non-small cell lung cancer?
    Arriola, Edurne
    Taus, Alvaro
    Casadevall, David
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 45 - 56
  • [37] Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
    Elena María Martínez-Navarro
    Joseba Rebollo
    Ramón González-Manzano
    Manuel Sureda
    Elena Evgenyeva
    Belén Valenzuela
    Francisco José Fernández
    Jerónimo Forteza
    Antonio Brugarolas
    Clinical and Translational Oncology, 2011, 13 : 812 - 818
  • [38] THE EFFECTS OF EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR INHIBITORS ON THE IMMUNE SYSTEM IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Meniawy, Tarek
    Lake, Richard
    Nowak, Anna K.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S374 - S374
  • [39] A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome
    Stasi, I.
    Farnesi, A.
    Vasile, E.
    Petrini, I.
    Luccchesi, M.
    Lupi, C.
    Sensi, E.
    Giannini, R.
    Fornaro, L.
    Caparello, C.
    Pasquini, G.
    Puppo, G.
    Finale, C.
    Barletta, M.
    Chella, A.
    Allegrini, G.
    Falcone, A.
    Fontanini, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
12345